Haematologica, Vol 92, Issue 10, 1415-1418 doi:10.3324/haematol.11413
Copyright © 2007 by Ferrata Storti Foundation
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Gertz, M. A.
Right arrow Articles by Gastineau, D. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Gertz, M. A.
Right arrow Articles by Gastineau, D. A.
Related Collections
Right arrowRelated Article

Amyloidosis

Effect of hematologic response on outcome of patients undergoing transplantation for primary amyloidosis: importance of achieving a complete response

Morie A. Gertz, Martha Q. Lacy, Angela Dispenzieri, Suzanne R. Hayman, Shaji K. Kumar, Nelson Leung, Dennis A. Gastineau

From the Division of Hematology (MAG, MQL, AD, SRH, SKK, DAG) and the Division of Nephrology and Hypertension (NL), Mayo Clinic, Rochester, Minnesota, USA

Correspondence: Morie A. Gertz, MD, Division of Hematology, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA. E-mail: gertz.morie{at}mayo.edu

Our objective was to determine whether the goal of high-dose therapy should be a partial hematologic response or a complete response. We analyzed 282 consecutive stem cell transplant patients. A partial hematologic response was achieved in 108 patients (38%), and 93 (33%) achieved a complete hematologic response. Survival rates of patients with complete, partial, or no response were significantly different (p<0.001), even after eliminating bias from early death. The degree of response was affected by the intensity of chemotherapy conditioning, septal thickness, and cardiac biomarkers. Hematologic response translates to longer survival.

Key words: amyloidosis, chemotherapy, complete response, immunoglobulin free light chain, stem cell transplant, survival.


Related Article

Bortezomib in the treatment of AL amyloidosis: targeted therapy?
Roberto Sitia, Giovanni Palladini, Giampaolo Merlini
Haematologica 2007 92: 1302-1307. [Full Text] [PDF]



This article has been cited by other articles:


Home page
BloodHome page
R. L. Comenzo
How I treat amyloidosis
Blood, October 8, 2009; 114(15): 3147 - 3157.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
D. E. Reece, V. Sanchorawala, U. Hegenbart, G. Merlini, G. Palladini, J.-P. Fermand, R. A. Vescio, X. Liu, Y. A. Elsayed, A. Cakana, et al.
Weekly and twice-weekly bortezomib in patients with systemic AL amyloidosis: results of a phase 1 dose-escalation study
Blood, August 20, 2009; 114(8): 1489 - 1497.
[Abstract] [Full Text] [PDF]


Home page
haematolHome page
G. Palladini and G. Merlini
Current treatment of AL amyloidosis
Haematologica, August 1, 2009; 94(8): 1044 - 1048.
[Full Text] [PDF]


Home page
haematolHome page
I. I. van Gameren, M. H. van Rijswijk, J. Bijzet, E. Vellenga, and B. P. Hazenberg
Histological regression of amyloid in AL amyloidosis is exclusively seen after normalization of serum free light chain
Haematologica, August 1, 2009; 94(8): 1094 - 1100.
[Abstract] [Full Text] [PDF]


Home page
Lab MedHome page
D. Siegel, E. Bilotti, and K. H. van Hoeven
Serum Free Light Chain Analysis for Diagnosis, Monitoring, and Prognosis of Monoclonal Gammopathies
Lab Med, June 1, 2009; 40(6): 363 - 366.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
A. D. Wechalekar, H. J. Lachmann, H. J. B. Goodman, A. Bradwell, P. N. Hawkins, and J. D. Gillmore
AL amyloidosis associated with IgM paraproteinemia: clinical profile and treatment outcome
Blood, November 15, 2008; 112(10): 4009 - 4016.
[Abstract] [Full Text] [PDF]


Home page
haematolHome page
R. Sitia, G. Palladini, and G. Merlini
Bortezomib in the treatment of AL amyloidosis: targeted therapy?
Haematologica, October 1, 2007; 92(10): 1302 - 1307.
[Full Text] [PDF]